Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysisSpatio-temporal composition of the mitotic Chromosomal Passenger Complex detected using in situ proximity ligation assayOverexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesisTargeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsExcellent translational research in oncology: A journey towards novel and more effective anti-cancer therapiesCirculating tumor cells in breast cancerAcquired and intrinsic resistance in cancer immunotherapyMoving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designBiomarker validation and testingCancer biomarkersRebuilding cancer metastasis in the mouseThe role of histone demethylases in cancer therapyEarly phase clinical trials to identify optimal dosing and safetyBringing in health technology assessment and cost-effectiveness considerations at an early stage of drug developmentTumour heterogeneity and the evolution of polyclonal drug resistanceHematopoietic growth factors: personalization of risks and benefitsNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityHow animal models of leukaemias have already benefited patientsDNA methylation and microRNA dysregulation in cancerIntegrative analysis of cancer imaging readouts by networksTrials with 'epigenetic' drugs: an updateGarbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkersGenetically engineered mouse models of pancreatic adenocarcinomaInhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapyMouse models for studying angiogenesis and lymphangiogenesis in cancerBioinformatics and systems biologyGermline pharmacogenomics in oncology: decoding the patient for targeting therapyAcquired resistance to EGFR-targeted therapies in colorectal cancerMolecular pathology - the value of an integrative approachGenetically engineered mouse models of prostate cancerCancer immunotherapyActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Theranostic applications of antibodies in oncology.Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myelomaTumor cell dormancyEpigenetic determinants of metastasisCancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesHarnessing adaptive natural killer cells in cancer immunotherapyT-cell receptor gene therapy--ready to go viral?Hepatocellular carcinoma: Where there is unmet need
P1433
Q24301596-BD2DA286-C921-4EBD-B302-F6092EAE21F8Q24305490-64233C65-F679-4BC4-A513-291A9D564A2DQ24317766-824153C5-3BAB-4D60-9573-EF5686F86EE5Q24610287-90795D41-8A88-46DB-B1F4-589CDCE041ACQ26770133-BB84CFD4-73AF-4312-BE00-86BBE5345A31Q26774808-EC8663E5-479E-490A-A63C-F023924EBED0Q26827701-65372739-0316-44E2-A6E1-BFD2E62D3231Q26830525-692FE006-6ABD-47A3-BEBF-0A206E31B943Q26863672-69264E63-EAC2-40D6-A723-A09ACEB8F192Q26864429-72D926A5-4DEE-4CC8-8873-D3788304F435Q26864450-8C1A1E06-2CC3-4896-B382-1C210BC8CB15Q26864687-25B085A8-BCC5-4D46-A1F8-5E6F64771871Q26865076-FB35D267-FBD6-4BEB-8A1A-9B03335B6CEDQ26866095-F466B95E-CA97-4F81-8B09-393C14C1780FQ26866803-AE7C1FBC-48C4-44AD-BF5D-FDF04AC33EB2Q26866922-32A0498D-4DBC-4A82-A5C5-0BC56F7B5E59Q26992272-A6E044D1-03D8-4B38-B384-D43B5BF41C74Q26997702-BC732FA7-5BEB-4689-8731-4C31BDB82A2DQ26998741-445A2F39-5D9A-4336-A0B7-F9C2CDE8B920Q26999069-1C6D517B-16C5-4386-956F-0F7DD2C8A165Q27000542-18A49DA8-60F7-436F-B441-5EA9EBE927A1Q27001445-7D29B978-6B50-44AA-B9CC-6E7AC30312E1Q27002973-56C78926-0F9F-4DE1-94FC-4A33CF97410EQ27003218-A8CBC797-DA17-4171-B5EC-D1513E808ABEQ27003898-9A229136-59E7-4334-8D27-5033640717D4Q27005417-A83EF294-3E61-48A9-AF7D-C2515D2F60D2Q27022557-6E445517-676C-4F71-8FDC-2A9029B4F5C6Q27022741-52B9F5D2-C62F-49F0-A499-7101CA5FDB22Q27023628-B7BF43C5-34C9-493F-B9F7-4A92B351DEC6Q27026768-D8115B4A-B9E5-42C2-93D5-358458101801Q27026870-F9433098-D0D6-4284-AAF8-EA302E2199BAQ27308683-19207D77-56FF-480B-AEB9-509F43F64A98Q27693293-F3EC76AF-8187-47FB-AC6F-C858E4D17354Q27700745-7D3D862D-1807-47D0-A823-9D21314C8193Q28073065-5FD78B12-69B3-458D-BA34-48D66C393125Q28079377-2593ACDB-EF2B-4FDF-83FC-CB154E644ACAQ28080472-6B8C4D0A-53A1-4470-BFC2-E70B6F125CB0Q28081448-6EEC1243-BC23-47CD-8102-5EF612EEC4E6Q28081611-18D57E08-28DA-485B-9FBA-42E85C038DF0Q28084046-0ED30373-76D6-487F-8DAA-53A954F6B5EA
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Elsevier
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Molecular Oncology
@ast
Molecular Oncology
@de
Molecular Oncology
@en
Molecular Oncology
@es
Molecular Oncology
@fr
Molecular Oncology
@it
Molecular Oncology
@nl
type
label
Molecular Oncology
@ast
Molecular Oncology
@de
Molecular Oncology
@en
Molecular Oncology
@es
Molecular Oncology
@fr
Molecular Oncology
@it
Molecular Oncology
@nl
prefLabel
Molecular Oncology
@ast
Molecular Oncology
@de
Molecular Oncology
@en
Molecular Oncology
@es
Molecular Oncology
@fr
Molecular Oncology
@it
Molecular Oncology
@nl
P31
P243
P3181
P4616
P1055
P1058
P1156
5800207508
P1160
Mol. Oncol.
P1250
P1277
P1476
Molecular Oncology
@en